

Applicant(s): HAMANN et al.
Serial No.: 10/712,456 Group Art Unit: NA
Filed: November 13, 2006 Examiner: NA
Title: OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN
RECEPTOR FUNCTION

Certificate of Electronic Filing

I hereby certify that this correspondence is being delivered to the
USPTO by EFS web on May 2, 2008



Daniel Feigelson
Agent for Applicant
Registration No. 42,527

Date of Signature: May 2, 2008

Enclosed: Information Disclosure Statement

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(c)(2)

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby make of record in the instant application the documents listed on the attached Form 1449.

This information is being cited out of an abundance of caution in view of the decisions in *Akron Polymer Container v. Exxel Container*, 148 F.3d 1380 (Fed. Cir. 1998) and *McKesson Information Solutions v. Bridge Medical, Inc.*, 487 F.3d 897 (Fed. Cir. 2007).

Applicants respectfully request that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning

patentability of the present claims, and initial, sign, and date the enclosed Form 1449, and return a copy of the signed Form 1449 with the next U.S. Patent and Trademark communication to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By citing these references, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, or treatment of this cited information by this or another Patent Office, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited references. An early and favorable action is hereby requested.

Payment of fee of \$180 per 37 CFR 1.17(p) is being made concomitantly with the filing of this Information Disclosure Statement. The Commissioner is hereby authorized to charge any other fees that may be required, or credit any overpayment of same, to Deposit Account No. 08-1935, Reference No. 1073.134A.

Respectfully submitted,



Daniel Feigelson
Attorney for Applicant
Registration No. 42,527

Dated: May 2, 2008

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579